Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Monoclonal antibodies such as alemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with relapsed or refractory advanced mycosis fungoides or Sézary syndrome.
Key facts
- Study ID
- NCT00057967
- Run by
- Northwestern University
- People needed
- 37
- Starts
- 2000-07-01
- Expected to finish
- 2010-07-26
- Last updated by the study team
- 2019-02-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwestern University, Northwestern Medical Faculty Foundation — Chicago, Illinois, United States
- Veterans Affairs Medical Center - Lakeside Chicago — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.